{"slug":"semaglutide-trigeminal","verification":{"valid":true,"entries":2,"head":"120c1c197a154280c82853f64f0b2829eaa4a4ed21ed51c5ee899583d301f7f8"},"energy":{"passes":2,"tokens_in":11973,"tokens_out":2231,"tokens_total":14204,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"120c1c197a154280c82853f64f0b2829eaa4a4ed21ed51c5ee899583d301f7f8"},"provenance":[{"ts":"2026-06-30T00:17:01.075Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semaglutide for Trigeminal\nSlug: semaglutide-trigeminal\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"semaglutide\",\"name\":\"Semaglutide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semaglutide\",\"name\":\"Semaglutide\",\"section_title\":\"Why Semaglutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\",\"**What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\",\"**Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\\n2. **What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\\n3. **Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-c","response":"{\n  \"slug\": \"semaglutide-trigeminal\",\n  \"title\": \"Semaglutide for Trigeminal Issues: Evidence Review\",\n  \"body\": \"## What's breaking down\\nTrigeminal neuralgia involves sudden, severe facial pain from irritation or damage to the trigeminal nerve. Common factors include blood vessel compression, demyelination, or inflammation around the nerve root. Metabolic stress from excess body weight can add systemic inflammation and mechanical strain on tissues, potentially worsening nerve repair capacity in some people. Degeneration outpaces repair when these layers combine.\\n\\n## Why Semaglutide might help you\\n1. **What keeps failing:** Weight-related joint and disc overload; metabolic stress on repair capacity.\\n2. **What Semaglutide is studied to do:** Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.\\n3. **Therefore for you:** If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\n## How these fit together\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Semaglutide** → metabolic load / body weight\\n\\n## What the evidence actually shows\\nNo clinical trials test semaglutide specifically for trigeminal neuralgia. Human data are limited to case reports of adverse effects. A 2025 case series in the American Journal of Health-System Pharmacy described four patients who developed allodynia (painful skin sensitivity) after semaglutide dose escalation to 2.4 mg weekly; symptoms resolved in some after stopping or continuing. (source s1) This links semaglutide temporally to a symptom seen in trigeminal neuralgia but does not prove causation for the condition itself. Preclinical work shows GLP-1 agonists can reduce brain inflammation in epilepsy mouse models, yet no trigeminal-specific animal studies exist here.\\n\\n## What scientists say\\nResearc","tokens_in":11973,"tokens_out":2231,"cost":0,"prev":"genesis","hash":"95366f04a86379da47be8c3eabdf7f60c7bbd2138640b16d1b4e61896feb25a1"},{"ts":"2026-07-17T02:41:50.303Z","model":"owner","action":"voxel_divide","prompt":"","input":"semaglutide-trigeminal","response":"19 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"95366f04a86379da47be8c3eabdf7f60c7bbd2138640b16d1b4e61896feb25a1","hash":"120c1c197a154280c82853f64f0b2829eaa4a4ed21ed51c5ee899583d301f7f8"}]}